jay brebner

Four Biotech Stocks to Play the Sector Pullback

but hey if you can't beat em - join em.

these stocks are sure to triple before ASCO 2010:

LPTN, EXEL, PPHM, MITI,

and big partnerships for these by q2 2010 XOMA and RNN .

buy them NOW! please.

Four Biotech Stocks to Play the Sector Pullback

user476730 - I agree with you its wrong - especially when you are touting cancer stocks which carry extra emotional baggage for some investors. But that's the nature of the market - it aint kindergarten. Vinny is doing what many hedge funds do. it takes balls to do it but its a souless existence. but the pay is pretty good I'm sure. like I said emptor caveat.

Four Biotech Stocks to Play the Sector Pullback

Vinny has made it his way with good old American initiative and a tiny bit of greed. His whole life (traveling, entertainment, meals, etc.) is a tax write of as long as he blogs about it on his site. I'm sure he is getting some shares of all these companies somehow and making a good deal of dough but this is America and this is how money is made these days -- Emptor caveat. If it's OK for Goldman it should be OK for Vinny. He's the one at the keyboard every day (unless he's paying some high school kid to write this stuff) so give him his due and move on.

BioDelivery Sciences Opportunity, Beware Cel Sci Bashers

1996 - DEO/PM? not sure what that is.

A friend just got through treatment for a tumor in the tonsils. He has been a swimmer for many years and it was HPV positive. Gardasil is not an adjuvant Tx now but if I had a tumor removed that was HPV+ I would demand Gardasil for prevention of a recurrence.

BioDelivery Sciences Opportunity, Beware Cel Sci Bashers

also - the incidence of head and neck cancers are increasingly associated with human papilloma virus. so the new HPV vaccines will be part of a treatment after surgical resection. there will be an estimated 35,000 new cases of head and neck cancer in 2009. at least 1/3 will be associated with HPV. The EGFR inhibitors are showing quite successful in treating most H&N tumors so their use will go up. the number of operable cases that will be candidate for multikine is not that big. I'm sure CVM is planning on getting approved for more sites but there will be so many vaccines and dendritic cell vaccines in a few years that the competition will be tough. That's on top of the fact that the treatment itself is in doubt.

BioDelivery Sciences Opportunity, Beware Cel Sci Bashers

BooBoo -
I worked in a lab at an NCI Cancer Center for a number of years, went to every seminar or talk I could. current nobel prize winner and several future winners (Frank McCormick - founder of Onyx) were in the same building and the Questions/discussions after each friday afternoon guest lecture were intense. One of my jobs in the lab was to research every candidate gene in a region of amplification or loss from our arrayCGH, (look it up). The education was invaluable. you can read one of our papers here
genome.cshlp.org/conte...

If multikine works it will prove just about the entire War on Cancer a waste of time. while this is possible it is not probable as Vinny claims. I got in this stock as an H1N1 play and have since got out but the pumping here is, in my opinion, unconscionable for someone who claims to be looking out for the small investor. there is much more risk in the multikine play than Vinny cares to admit. he is long and is a cheerleader - plain and simple.

BioDelivery Sciences Opportunity, Beware Cel Sci Bashers

"but I'm inclined to believe that the attackers of Cel Sci are making out financially somehow, because why else would you pick on a company that is developing two potentially life saving treatments - unless you're just that much of a cruel and heartless coward."

that's not a "positive outlook". that's a pump. AF has an opinion and you have an opposite opinion. neither of you can predict the future. multikine has a low chance of getting any market share even if it gets approved. there are better and more sustainable ways to modulate the tumor immune microenvironment.